Inhalable Insulin Mimics Early-Phase Response to Reduce Hypoglycemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin therapies, particularly for type 1 and type 2 diabetes, often result in frequent hypoglycemic events due to the suboptimal pharmacodynamics of subcutaneous insulin administration, which fails to mimic the natural early-phase insulin response, leading to inadequate glycemic control and increased risk of severe hypoglycemia.
Innovation Solution
The development of an ultra-rapid, ultra-fast acting inhalable insulin formulation comprising insulin and fumaryl diketopiperazine, administered via a dry powder inhaler, which mimics the natural early-phase insulin response by providing a rapid spike and subsequent decline in serum insulin levels, thereby reducing glucose excursions and minimizing hypoglycemic episodes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous insulin administration is used, then insulin delivery is achieved, but the pharmacodynamics fail to mimic natural early-phase insulin response, resulting in inadequate glycemic control and increased hypoglycemia risk
Solution Approach 1:
The patent uses an inhalable insulin formulation as an intermediary delivery method between traditional subcutaneous injection and natural physiological insulin response. The pulmonary delivery system enables ultra-rapid absorption through the alveolar-capillary interface, mimicking the natural early-phase insulin spike that occurs after meal ingestion, thereby improving glycemic control while reducing hypoglycemia risk
Solution Approach 2:
The patent changes the physical and pharmacokinetic parameters of insulin delivery by transitioning from subcutaneous injection to inhalable formulation. This results in ultra-rapid absorption with peak serum insulin levels achieved within minutes, closely replicating the natural early-phase insulin response pattern, thereby resolving the contradiction between reliable glycemic control and hypoglycemia prevention
2Speed
If traditional rapid acting insulin analogs are administered, then blood glucose levels are reduced, but hypoglycemic events occur frequently due to prolonged insulin action
Solution Approach 1:
The patent implements a biphasic insulin secretion pattern through the inhalable formulation, where an initial ultra-rapid spike in serum insulin levels (early phase) is followed by a gradual decline (late phase). This periodic action pattern mimics natural physiological insulin response, providing rapid glucose control while preventing prolonged hypoglycemia through the natural tapering of insulin activity
3Reliability
If subcutaneous insulin therapy is used, then diabetes is treated, but weight gain occurs as a side effect
Solution Approach 1:
The patent changes the pharmacokinetic parameters of insulin delivery by using inhalable formulation with ultra-rapid absorption and shorter duration of action. This prevents the prolonged hyperinsulinemic state associated with subcutaneous injection, thereby reducing insulin-mediated weight gain while maintaining effective diabetes treatment through improved glycemic control
Data Source
AI summary
An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.